Archive: Company News

Company News: Anergis Closes CHF 18 Million Series A Financing Round to Develop its Innovative Allergy Vaccines and Expands its Board of Directors

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors. Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called Contiguous Overlapping Peptides (COPs), is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widely spread condition in developed countries.

The financing round was co-led by three major European funds with extensive biotech experience: Vinci Capital-Renaissance PME (Lausanne, Switzerland), BioMedInvest (managed by BioMedPartners AG, Basel, Switzerland) and Sunstone Capital (Copenhagen, Denmark). The syndicate was also joined by Esperante (Limhamn, Sweden), Initiative Capital Romandie (Lausanne, Switzerland) and by private investors. Up until now, Anergis has invested CHF 3 million in its innovative allergy vaccines. These funds were raised from private investors and from a grant by the Swiss Innovation Fund (CTI).

The newly joining investors also bring substantial pharmaceutical experience and know-how to Anergis: Patrick Scherrer (representing Vinci Capital-Renaissance PME), Markus Hosang (representing BioMedInvest) and Sten Verland (representing Sunstone Capital) have joined the Anergis Board of Directors. The Board will be chaired by André J. Mueller, a professional with unique executive and non-executive experience in biotech ventures, which he gained with Biogen and Actelion and as the Chairman of the Boards of Cerenis Therapeutics (Toulouse) and Addex Pharmaceuticals (Geneva).

Company News: bubbles & beyond closes second financing round

bubbles & beyond, a technology company focusing on customized intelligent fluids, has announced the successful closing of a second financing round. All existing investors – LBBW Venture Capital, S-Beteiligungen, Hightech-Gruenderfonds and KfW – participated in the round, which totals EUR 1.2m.

The new funds will be used to strengthen the international market presence of bubbles & beyond and to broaden its internal development capacities in order to meet the increasing demand for customized intelligent fluids™ in various industry sectors. This includes diversified commercialization opportunities in the printing industry, microelectronics, and facility cleaning sectors in Europe and Japan. bubbles & beyond already markets products for graffiti removal as well as cleaning and preservation of building structures on the market. A product portfolio of professional cleaning agents for print rolls will be launched soon. In addition, there is considerable market demand for bubbles & beyond´s intelligent fluids™ in functional cosmetics.

Read more

Company News: bubbles & beyond adds seasoned executives and scientists to it board

bubbles & beyond, a technology company focusing on intelligent fluids, has announced the appointment of several prestigious scientists and executives to its advisory board. The board´s goal is to support the company in the further expansion and commercialization of its product portfolio. Dr. Hubert Bader, Managing Director and Equity Partner of Chemadvice GmbH, Jean-Michel Kennes, previously Head of L’Oréal Germany, and Prof. Dr. Friedrich Kremer of Leipzig University have been appointed to the board, which will be chaired by investor representative Mattias Goetz, General Manager at LBBW Venture Capital.

bubbles & beyond focuses on the development of customized intelligent fluids for industrial, cosmetic, and medical applications. Industrial applications include next-generation cleaning agents for the printing industry, graffity removal and surface protection, or I&I.  Based on its proprietary intelligent fluids™ platform, bubbles & beyond can create phase fluids, which allow for unique physical effects and a stunning performance as well as a broad range of different product types and applications. These solutions are exclusively composed of approved, gentle ingredients, which have been tried and tested for a long time.

Company News: Jomaa Pharma and Medicines for Malaria Venture to Co-develop Novel Malaria Treatment Based on Fosmidomycin

– New treatment options for drug-resistant malaria types –

Jomaa Pharma GmbH, a German biopharmaceutical company engaged in malaria chemotherapy, and Medicines for Malaria Venture (MMV), a not-for-profit research foundation, announced today that they have signed a Memorandum of Understanding for the joint development of fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria. Fosmidomycin is a molecule that possesses antimalarial and antibacterial activity. The stimulus for this co-development project follows reports of the emergence of artemisinin resistance on the Thai-Cambodian border.

The prospect of overcoming this drug-resistance through fosmidomycin when combined with piperaquine is considered to be very promising and constitutes the basis of the partnership between Jomaa Pharma and MMV.

1 121 122 123 132